



Attorney Docket No. VPI/02-05 US

DW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/749,121
Confirmation No.: 3285
Filing Date: December 30, 2003
Examiner: Not Yet Assigned
Group art unit: 1625
Applicants: Saunders et al.
For: SULFHYDANTOINS AS PHOSPHATE ISOSTERES

September 12, 2005
Cambridge, Massachusetts

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

(a) Pursuant to 37 C.F.R. §1.56, it is requested that the documents listed on the accompanying Form 1449/PTO be considered and made of record in the above-identified patent application.

Copy(ies) of references Citation No(s). A1-A6; B1; C1-C11 are attached.

Copy(ies) of references Citation No(s). _____ was/were filed in application U.S. Application No(s). _____ filed _____, from which this application claims priority under 35 U.S.C. § 120.).

A copy of the International Search Report received in the corresponding PCT Application No. PCT/US03/41630 is attached herewith.

(b) No fee is believed due because:

The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

The Information Disclosure Statement is being concurrently filed with the above-identified application.

The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

Applicants: Saunders et al
Application No.: 10/749,121

(c) The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

(d) The Information Disclosure Statement is being filed on or before the payment of the issue fee; and

Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or

No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and

The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.

Applicants: Saunders et al
Application No.: 10/749,121

The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS LETTER IS ATTACHED.

Respectfully submitted,


Michael C. Badia
Michael C. Badia, Reg. No. 51,424
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6467
Fax: (617) 444-6483

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Mail Stop: Amendment, P.O. Box 1450, Alexandria, VA 22316-1450 on 9-12-05.



9/12/05

Date of Signature



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On September 12, 2005
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (A1-A6; B1, C1-C11); and
4. Return Postcard Receipt.



Signature

Lisa M. Romano
Typed or printed name of person signing Certificate



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Information Form 1449/PTO		Application Number	10/749,121
		Filing Date	December 30, 2003
		First Named Inventor	Saunders et al.
		Group Art Unit	1644
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	VPI/02-05 US

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,541,168	7/30/96	Sterling Winthrop Inc.	514	92	10/2/94
	A2	5,750,546	5/12/98	Sanofi Winthrop Inc.	514	342	12/2/94
	A3	5,512,576	4/30/96	Sterling Winthrop Inc.	514	258	12/2/94
	A4	5,494,925	2/27/96	Sterling Winthrop Inc.	514	362	12/2/94
	A5	5,550,139	8/27/96	The Wichita State University	514	362	8/27/96
	A6	5,556,09	9/17/96	Sanofi Winthrop Inc.	514	362	12/2/94

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B1	EP	WO 03/082841 A1	Novartis AG	9 October 2003	

OTHER NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Mantegani et al., "Synthesis And Antihypertensive Activity Of 2,4-Dioxoimidazolidin-1-yl And Perhydro-2,4-Dioxopyrimidin-1-yl Ergoline Derivatives", IL Farmaco, 53 (4): 293-304 (1998)
	C2	Bright et al, "Competitive Particle Concentration Fluorescence Immunoassays For Measuring Anti-Diabetic Drug Levels In Mouse Plasma", Journal of Immunological Methods, 207 (1): 23-31 (1997)
	C3	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. 3, 290-300 (2001)
	C4	Kuang et al., "A General Inhibitor Scaffold for Serine Proteases with a (Chymo)trypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors", J. Am. Chem. Soc. 121 (35): 8128-8129 (1999)
	C5	Groutas et al, "Potent and Specific Inhibition of Human Leukocyte Elastase, Cathepsin G and Proteinase 3 by Sulfone Derivatives Employing the 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide Scaffold", Bioorganic & Medicinal Chemistry 6 (6): 661-671 (1998)
	C6	Groutas et al, "Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold" Biochemistry, 36(16): 4739-4750 (1997)
	C7	Dewynter et al, "Synthesis of Pseudonucleosides Containing Chiral Sulfahydantoins as Aglycone (II)", Tetrahedron , 52 (3): 993-1004 (1996)
	C8	Muller et al, "A General Synthesis of 4-Substituted 1, 1-Dioxo-1,2,5-thiadiazolidin-3-ones Derived from alpha Amino Acids", J. Org. Chem., 54 (18): 4471-4473 (1989)
	C9	Lee et al, "3-Oxo and 3-Imino-4-substituted-1,2,5-thiadiazolidine 1,1-Dioxides: Synthesis, Spectral Properties, and Selected Chemistry", J. Org. Chem., 54 (13): 3077-3083 (1989)
	C10	Tremblay et al, "Efficient Solid-Phase Synthesis of Sulfahydantoins", J. Comb. Chem., 4 (5): 429-435 (2002)
	C11	Albericio et al, "Solid Phase synthesis of Sulfahydantoins", Tetrahedron Letters, 41 (17) 3161-3163 (2000)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.